[{"orgOrder":0,"company":"Veru","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Veru \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Blue Water Vaccines \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"Blue Water Vaccines \/ IQVIA"},{"orgOrder":0,"company":"Onconetix","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Onconetix","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconetix \/ Blue Water Vaccines","highestDevelopmentStatusID":"15","companyTruncated":"Onconetix \/ Blue Water Vaccines"},{"orgOrder":0,"company":"Prague Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"CZECH REPUBLIC","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Urology","graph2":"Approved FDF","graph3":"Prague Scientific","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Prague Scientific \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Prague Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Almirall \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"EMS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Dermatology","graph2":"Phase III","graph3":"EMS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"EMS \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"EMS \/ Inapplicable"},{"orgOrder":0,"company":"Triple Hair","sponsor":"Akums Drugs & Pharmaceuticals Ltd","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Finasteride","moa":"||SRD5A2","graph1":"Dermatology","graph2":"Phase II","graph3":"Triple Hair","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Triple Hair \/ Akums Drugs & Pharmaceuticals Ltd"}]

Find Clinical Drug Pipeline Developments & Deals for Finasteride (Proscar)

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Finasteride (Proscar)

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

69 API Suppliers, 11 USDMF, 10 CEP/COS, 6 JDMF, 11 EU WC, 36 KDMF, 20 NDC API, 19 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

FINISHED DOSAGE FORMULATIONS

247 FDF Dossiers, 24 FDA Orange Book, 135 Europe, 24 Canada, 20 Australia, 10 South Africa, 34 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 5MG, TABLET;ORAL - 1MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 4 SPI Pharma, 6 DKSH, 4 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 6 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 9 Actylis, 1 Aeon Procare, 8 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 25 BASF, 1 CD Formulation, 1 Clariant, 10 Corel Pharma Chem, 7 DFE Pharma, 1 Esteem Industries, 2 Finar, 10 Gangwal Chemicals, 4 Ideal Cures, 4 Ingredion Pharma Solutions, 24 Kerry, 3 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 12 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 3 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 18 Roquette, 14 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 11 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

53 Fillers, Diluents & Binders, 44 Coating Systems & Additives, 29 Granulation, 29 Direct Compression, 27 Disintegrants & Superdisintegrants, 25 Solubilizers, 24 Thickeners and Stabilizers, 23 Controlled & Modified Release, 22 Topical, 17 Lubricants & Glidants, 16 Parenteral, 15 Film Formers & Plasticizers, 13 Co-Processed Excipients, 10 Taste Masking, 9 Emulsifying Agents, 8 Chewable & Orodispersible Aids, 7 Rheology Modifiers, 6 API Stability Enhancers, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 20 News #PharmaBuzz

GLOBAL SALES INFORMATION

15 US Medicaid Prescriptions, 122 Regulatory FDF Prices, 11 Annual Reports

MARKET PLACE

23 APIs, 9 FDF Dossiers

PATENTS & EXCLUSIVITIES

7 Health Canada Patents

7 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Dr. Reddy's Laboratories

India

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Finasteride,Inapplicable

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 21, 2010

Lead Product(s) : Finasteride,Inapplicable

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Dr. Reddy's Laboratories

India

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Finasteride,Inapplicable

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 21, 2010

Lead Product(s) : Finasteride,Inapplicable

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Dr. Reddy's Laboratories

India

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Finasteride,Inapplicable

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 28, 2010

Lead Product(s) : Finasteride,Inapplicable

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

04

Dr. Reddy's Laboratories

India

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Lead Product(s) : Finasteride,Inapplicable

Therapeutic Area : Undisclosed

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 28, 2010

Lead Product(s) : Finasteride,Inapplicable

Therapeutic Area : Undisclosed

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Dr Reddy Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

05

Triple Hair

U.S.A

EPSC

Not Confirmed

06

Onconetix

U.S.A

EPSC

Not Confirmed

07

Blue Water Vaccines

U.S.A

EPSC

Not Confirmed

08

Veru

U.S.A

EPSC

Not Confirmed

09

Veru

U.S.A

EPSC

Not Confirmed

10

Prague Scientific

Czech Republic

EPSC

Not Confirmed

1
2
3